Actavis has suddenly become the belle of the ball. The Wall Street Journal reports that Novartis is now entertaining a $16 billion bid for the generics maker after a $13 billion offer from Valeant and a $15 billion bid from Mylan both fell flat.
We thought Actavis had a love triangle going with potential merger partners Warner Chilcott and Valeant Pharmaceuticals, as an analyst dubbed it earlier this week. Now, news emerges that it's more like a love quadrangle, with rejections on two sides.
Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.
A year after HemCon Medical Technologies filed for Chapter 11 reorganization following the loss of a patent fight, the Oregon maker of gels and dressings has been sold.
As its net profits careen into the red, Theragenics is considering a buyout offer worth up to $71.4 million from private equity outfit Juniper.
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
Instem has bought a ticket to play a larger role in the market for early-stage clinical trials. The provider of IT solutions has acquired Logos Technologies, which provides electronic data-capture (EDC) software for pharma, biotech and CRO companies.
Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.